Trisalus Life Sciences (TLSI) Registration Filing summary

Company overview and business model

• Focuses on oncology, developing drug delivery technology to improve therapeutic delivery to liver and pancreatic tumors, and integrating this with investigational immunotherapeutic nelitolimod for these indications.

• Developed an organ-specific platform to address high intratumoral pressure and immunosuppressive tumor environments, aiming to improve patient outcomes.

• Operates as an emerging growth and smaller reporting company, taking advantage of reduced public company reporting requirements.

Financial performance and metrics

• As of October 21, 2024, 30,491,072 shares of Common Stock were outstanding.

• The last reported sales price of Common Stock on October 21, 2024, was $4.25 per share.

Use of proceeds and capital allocation

• Will not receive any proceeds from the sale of shares by Selling Securityholders; all proceeds go to the Selling Securityholders.

• Will pay expenses related to registration, but Selling Securityholders bear commissions and discounts.